ABSTRACT
Multiple Sclerosis [M.S] is one of the prevalent diseases of the central nervous system which cause disability in young adults. This appears as neural signs in different parts and various times. The main defect is local deterioration or destruction of myelin tissue in the brain and spinal cord. Profound fatigue is one the most common symptoms of this disease. Because MS is prevalent in middle ages, so the presence of this symptom affects the life and activity of the patient; In these ages people have high amount of activities and this functional disorder creates many difficulties for daily works in patient. For this reason, fatigue problem in patients, always, have caught the attention of researchers. Despite numerous studies, still the exact reason for producing fatigue have not been mentioned; But several mechanisms have been discussed, such as: autoimmune mechanism of the disease, Involvement and disorder of endocrine system, involvement of central nervous system and de-synchronization of autonom system. Among these, autoimmune mechanism is considered as a main role in producing fatigue. Lack of proper knowledge regarding exact fatigue mechanism several problems in its treatment. Evaluation is the first step for controlling fatigue, which is done through various tests. Clear and proper evaluation can be obtained by these tests. After evaluation, non-drug and finally drug procedures are helpful. In non-drug treatment the focus is on: sport exercises, suitable diet program, identification and improvement of the patient psychotic disorders, energy conservation methods. Finally, the use of drugs such as Amantadine, Pemoline and Modafini is recommended for fatigue treatment
Subject(s)
Humans , Fatigue/etiology , Fatigue/therapy , Multiple Sclerosis , Prevalence , Central Nervous System Diseases , Myelin Sheath , Brain , Spinal Cord , Autoimmune Diseases , Exercise , Diet , Psychotic Disorders , Amantadine , PemolineABSTRACT
O tratamento da narcolepsia visa seus dois sintomas principais, a sonolência excessiva diurna e a cataplexia. A primeira é usualmente controlada com anfetmina, metilfenidato e pemoline. Mais recentemente, inibidores da MAO, e principalmente os inibidores seletivos de MAO-A e B têm mostrado resultados promissores, com a selegilina. Modafinil, um estimulante alfa-1-adrenérgico tem também evidenciado bons resultados. A cataplexia, por sua vez, é geralmente tratada com antidepressivos tricíclicos. Dentre as novas drogas, sem efeito colateral antropínico, temos o hidrocloreto de viloxazina, um bloqueador de recaptaçäo da noradrenalina
Subject(s)
Humans , Amphetamine , Amphetamine/therapeutic use , Cataplexy/drug therapy , Sleep Wake Disorders/drug therapy , Methylphenidate , Methylphenidate/therapeutic use , Narcolepsy/drug therapy , Pemoline , Pemoline/therapeutic use , Antidepressive Agents, Second-Generation/therapeutic use , Antidepressive Agents, Second-Generation/administration & dosage , Antidepressive Agents, Tricyclic/therapeutic use , Antidepressive Agents, Tricyclic/administration & dosage , Monoamine Oxidase Inhibitors , Monoamine Oxidase Inhibitors/therapeutic use , Selegiline , Selegiline/therapeutic useABSTRACT
Tomando por referencial a definição de caso da Síndrome da Fadiga Crônica (SFC), realizada pelo Center of Disease Control em 1988, os autores fazem uma revisão desta entidade nosológica nos seus aspectos Etiológico, Epidemiológico, Diagnóstico, Terapêutico e Prognóstico. Fazendo um resgate histórico do termo Neurastenia e acentuando as suas semelhanças com a SFC, até então não sistematizada nas classificações de desordens mentais vigentes